Iron Supplements and the Gut Microbiome in Reproductive-Age Women: A Randomized Controlled Trial

What the study examined and how

Iron deficiency is the most common micronutrient deficiency worldwide and disproportionately affects menstruating and reproductive-age women, for whom oral iron salts such as ferrous fumarate, ferrous sulfate, and ferrous bisglycinate are first-line treatment. A recurring concern is that only a fraction of an oral iron dose is absorbed in the proximal small intestine; the unabsorbed remainder travels to the colon, where it becomes a potential nutrient source for resident and pathogenic microbes. Trials in low-income settings had suggested this luminal iron can reshape the gut microbiota, but data from high-income populations with lower baseline enteropathogen burden were scarce.

Elms and colleagues (Journal of Nutrition, 2024) addressed this gap with a prospective, parallel-group, double-blind, randomized controlled trial conducted in South Australia. Eighty-two non-pregnant females aged 18-45 years were randomized to receive either iron (65.7 mg elemental iron as ferrous fumarate) or a matched placebo daily for 21 days, with 80 participants completing the protocol. Fecal samples were collected at baseline and after 21 days of supplementation and profiled by 16S rRNA gene amplicon sequencing.

The pre-specified outcomes were community-level (beta) diversity, assessed by weighted UniFrac distance (a phylogeny-aware, abundance-weighted measure of between-sample dissimilarity), alpha diversity, and the relative abundance of common bacterial taxa. The investigators paid particular attention to Escherichia-Shigella, a genus of Enterobacteriaceae that includes opportunistic enteric pathogens and that has been reported to expand under iron exposure in more susceptible populations.

The key findings

Over the 21-day intervention, iron supplementation did not produce a statistically significant change in fecal microbiome composition relative to placebo. There was no significant between-group difference in weighted UniFrac dissimilarity (P = 0.52), indicating that overall community structure was comparable across the two arms.

There were likewise no significant differences in the relative abundance of common bacterial taxa or, notably, in Escherichia-Shigella, the pathogen-associated genus of primary interest. The authors concluded that oral iron supplementation did not detectably affect the gut microbiome of non-pregnant women of reproductive age in this high-income setting. As a well-conducted negative result, the study is best read as bounding, rather than confirming, the conditions under which supplemental iron perturbs the gut community.

The mechanism: luminal iron, siderophores, and pathogen competition

The biological rationale for expecting an effect rests on how iron is partitioned in the gut. Absorption is tightly regulated and incomplete, so a substantial fraction of an oral dose reaches the colonic lumen. Many enteric pathogens and facultative anaerobes in the family Enterobacteriaceae, including Escherichia, Shigella, and Salmonella, are avid iron scavengers that deploy secreted siderophores and other metallophores to capture iron and gain a competitive edge. By contrast, several beneficial commensals such as Bifidobacterium and Lactobacillus have comparatively modest iron requirements. In principle, a surge of bioavailable luminal iron can therefore tilt the competitive balance toward Enterobacteriaceae.

This mechanism intersects with host nutritional immunity, the strategy by which the host withholds iron and other transition metals from microbes to limit their growth. Excess unabsorbed iron can partially override that restriction at the mucosal surface. In infant and adult trials in low-income, high-pathogen-burden settings, iron fortification and supplementation have been associated with increased abundance of enteropathogens, reduced beneficial taxa, and rising fecal calprotectin, a marker of intestinal inflammation.

Several features of the present trial likely explain the null result: a relatively short 21-day exposure, a healthy and well-nourished cohort with an established, resilient baseline microbiome, good sanitation and low ambient enteropathogen pressure, and efficient host iron handling that leaves less iron in the lumen. A related dose-response study in middle-aged women reported that microbiome effects, where present, tend to be modest and dose-dependent, consistent with the idea that host and environmental context, not iron alone, governs whether luminal iron reshapes the community.

How it fits the metal-microbiome-disease axis

Microbial Metallomics tracks the axis in which metal exposure reshapes the microbiome and microbiome disruption drives disease. Iron sits at the essential-nutrient end of that spectrum rather than the heavy-metal-toxicant end, but it obeys the same underlying logic: a metal delivered to the gut lumen can redistribute microbial fitness by feeding metal-scavenging pathogens and altering the interplay between metalloregulation and host nutritional immunity.

This trial supplies an important, honest counterweight to that narrative. It demonstrates that in a well-nourished, low-pathogen, high-income population, a therapeutic course of iron is not sufficient on its own to disrupt the microbiome. The microbiome-disruption step of the axis appears context-dependent, more readily triggered where baseline pathogen load, luminal iron availability, dose, and duration are higher, as seen in low-income-setting trials. Rather than weakening the axis, the result sharpens it: it identifies the conditions that determine whether a metal exposure translates into measurable community change, which is a prerequisite for any downstream disease link.

For clinical practice, the finding is reassuring. Short-term oral iron to correct or prevent deficiency in otherwise healthy reproductive-age women does not appear to come at the cost of a destabilized gut microbiome, even though the same intervention warrants closer scrutiny in populations where the axis is more likely to be engaged.

Limitations and interpretation

The trial's strengths, its randomized double-blind design and placebo control, are balanced by limitations that constrain generalization. The 21-day duration captures short-term dynamics but may miss slower community shifts; the sample was healthy and iron-replete-to-deficient rather than severely anemic; and 16S rRNA gene sequencing resolves taxa to genus level and cannot fully characterize strain-level or functional (metagenomic) changes in iron-acquisition pathways. Absence of a detectable effect at the community level does not exclude subtle functional or metabolomic changes.

Read alongside secondary analyses from Cambodian women of reproductive age and dose-response work in middle-aged women, the evidence base points to a consistent conclusion: whether supplemental iron reshapes the gut microbiome depends heavily on setting, dose, duration, and host baseline, not on iron exposure in isolation.